Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viatris Inc. - Common Stock (NQ:VTRS)

15.88 -0.10 (-0.63%)
Streaming Delayed Price Updated: 10:43 AM EST, Feb 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viatris Inc. - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
20 21 Next >
News headline image
Beat Inflation With These 3 High-Yielding Dividend Stocks In Health Care Sector From Wall Street's Most Accurate Analysts ↗
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
Topics Economy
News headline image
Are defensive sectors ready to outshine growth in 2024?
Is 2024 the year defensive stocks rotate into leadership? As the year gets underway, defensives such as healthcare, energy, utilities and consumer staples lead. 
Via MarketBeat
News headline image
Why Is Lung Disease Focused Theravance Biopharma Stock Trading Lower Today? ↗
Theravance Biopharma Inc (NASDAQ: TBPH) announced results from the Phase 4 PIFR-2 study of Yupelri (revefenacin) inhalation solution, the only once-daily, nebulized long-acting muscarinic antagonist... 
Via Benzinga
News headline image
Tech Sell-Off Triggers Market Reset: Value Stocks Reach 7-Month High Versus Growth ↗
U.S. stock market suffered worst start in two decades, tech sell-off led to cautious investor shift to value stocks, notably IUSV & IUSG ETFs + top gainers MRNA, VTRS, TNL, LVS & VAC. 
Via Benzinga
Topics ETFs
News headline image
Recap: Viatris Q3 Earnings ↗
 
Via Benzinga
News headline image
2 Top Value Stocks to Buy in October ↗
These two blue chip stocks offer top-notch yields, attractive valuations, and solid long-term prospects. 
Via The Motley Fool
News headline image
VIATRIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Viatris Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Regeneron Celebrates Legal Win: Court Upholds Eylea Medication Patent ↗
Wednesday, a court ruling that found Viatris Inc's (NASDAQ: 
Via Benzinga
News headline image
3 Minutes To Boost Your Earnings: 3 Stocks With Over 3% Dividend Yields In Health Care Sector From Wall Street's Most Accurate Analysts ↗
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
News headline image
A Look Into Healthcare Sector Value Stocks ↗
 
Via Benzinga
News headline image
These 3 Dividend Stocks Are Undervalued Using This Key Valuation Metric ↗
Book value is a valuable metric for discovering undervalued stocks. These 3 dividend payers are trading below book value. 
Via Talk Markets
News headline image
Buy Alert: Analysts Say These 3 Growth Stocks Could Double in 2024 ↗
Often the best investments are out-of-favor and trade at silly cheap valuations. Check out three such growth stocks with huge upside. 
Via InvestorPlace
News headline image
7 Low P/E Stocks Poised to Rebound ↗
Each of these seven low P/E value stocks trades for under 10 times earnings, but could rise to a much higher valuation as sentiment improves. 
Via InvestorPlace
News headline image
Week In Review: Legend Partners DLL3 CAR-T Candidate With Novartis In $1.2 Billion Deal ↗
Legend Biotech partnered its DLL3 CAR-T candidates to Novartis in a $1.2 billion agreement, with $100 million offered upfront. Novartis will own worldwide rights to develop, manufacture, and... 
Via Talk Markets
News headline image
5 Value Stocks To Watch In The Healthcare Sector ↗
 
Via Benzinga
News headline image
3 Large-Cap Stocks to Buy Trading Below Book Value ↗
There aren’t too many large-cap stocks in the S&P 500 trading below book value. But here are three possibilities. 
Via InvestorPlace
Topics Stocks
News headline image
Ozempic Just Shrugged Off a Challenge From Viatris. What Does This Mean for Investors? ↗
Viatris now faces a narrower path to commercializing a generic copy of Ozempic. 
Via The Motley Fool
News headline image
Viatris Just Sold Off 3 Key Segments. Is It Still a Buy? ↗
There's a chance shareholders won't notice any difference. 
Via The Motley Fool
News headline image
2 Healthcare Dividend Stocks You'd Regret Not Buying on the Dip ↗
These stocks may not be for everyone, but income-seekers might find what they're looking for in them. 
Via The Motley Fool
News headline image
Obesity Drug Wegovy's Triumph to Catapult Novo Holdings In Golden Era Of Wealth Boost ↗
Novo Holdings, the controlling shareholder of Novo Nordisk A/S (NYSE: NVO), is bracing for a significant influx of capital stemming from the thriving success of the weight-loss drug Wegovy.  
Via Benzinga
News headline image
Earnings Scheduled For November 7, 2023 ↗
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter. 
Via Benzinga
News headline image
'Airbnb Has Foundational Cracks', Disney+ Follows Netflix On Subscription Sharing Crackdown, Microsoft's Nadella Criticizes Google's Exclusive Content Deals: Today's Top Stories ↗
Benzinga 
Via Benzinga
News headline image
Novo Nordisk Weight Loss Drug Patent Battle Against Viatris - Emerges As Winner ↗
Novo Nordisk A/S (NYSE: NVO) successfully defended two pivotal patent claims linked to the main ingredient in its popular weight-loss and diabetes drugs,  
Via Benzinga
Topics Intellectual Property
News headline image
Viatris Stock Bounds Higher As Divestitures Reach Nearly $7 Billion ↗
The company is retaining the rights to specific over-the-counter drugs in some markets. 
Via Investor's Business Daily
News headline image
Viatris Phase 1 Asset Divestiture Story: Plans To Sell Certain OTC Products, Women's Healthcare Business & More ↗
Viatris Inc (NASDAQ: VTRS) disclosed multiple deals to sell remaining assets to conclude Phase 1 of planned asset disposition by  
Via Benzinga
News headline image
Could Viatris Stock Help You Become a Millionaire? ↗
Viatris' broad portfolio gives the business lots of stability and plenty of opportunities -- but is there enough there for the stock to be a great long-term investment? 
Via The Motley Fool
News headline image
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields ↗
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
News headline image
Despite Efforts, Vulnerable Patients Still Face Barriers to Essential Medicines, Says New Report ↗
Despite significant initiatives by generic drug companies to broaden access to vital medicines, many vulnerable patients remain underserved, according to findings from a new study from the Access to... 
Via Benzinga
News headline image
NASDAQ: VTRS Shareholder Notice Investigation over Potential Wrongdoing by Certain Directors of Viatris Inc. ↗
San Diego, CA -- (SBWIRE) -- 09/22/2023 -- Certain directors of Viatris Inc.are under investigation concerning potential breaches of fiduciary duties. 
Via SBWire
News headline image
'Stocks In Monopolistic Bull Market': Wall Street Analyst Contemplates A Bright Future For Next Phase ↗
The analyst illustrated how the dominant force in stock market returns for 2023 has been the "Magnificent 7." 
Via Benzinga
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.